Trevena's Phase II Pain Drug Bests Morphine
This article was originally published in Scrip
Executive Summary
Trevena Inc.'s stock shot up this week on the news its post-operative pain drug met primary endpoints in a Phase IIb study – showing superiority over morphine.
You may also be interested in...
After APOLLO: Trevena Weighs Commercial Viability Of Opioid Oliceridine
A mixed bag of safety results for the new opioid Olinvo (oliceridine) in the Phase III APOLLO pain trials disappoints the market, but analysts are encouraged by the totality of the data and optimistic about approval.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.